Loading...
•
Dec 31, 2021
SIGA Technologies Q4 2021 Earnings Report
SIGA Technologies' financial performance significantly improved in Q4 2021, driven by increased product sales.
Key Takeaways
SIGA Technologies reported a substantial increase in revenue and net income for the fourth quarter of 2021, primarily due to increased product sales of oral TPOXX to the U.S. government. The company's strategic focus on health security and successful partnerships have contributed to its financial success.
Total revenues increased to $115.4 million in Q4 2021, compared to $37.8 million in Q4 2020.
Operating income rose to $94.0 million in Q4 2021, up from $26.8 million in Q4 2020.
Net income reached $73.2 million in Q4 2021, a significant increase from $20.1 million in Q4 2020.
Diluted income per share increased to $0.98 in Q4 2021, compared to $0.26 in Q4 2020.
SIGA Technologies
SIGA Technologies
SIGA Technologies Revenue by Segment
Revenue by Segment
Product sales & supportive services Revenue
CapyFin.comResearch and development Revenue
CapyFin.com Forward Guidance
The press release contains forward-looking statements regarding SIGA's development programs, timelines for bringing products to market, and the impact of COVID-19 on SIGA's business. Actual results may differ due to various risks and uncertainties.
Positive Outlook
- Continued progress in development programs.
- Potential for new products to reach the market.
- Ongoing government contracts provide a stable revenue stream.
- International expansion opportunities.
- Potential for alternative uses or formulations of TPOXX.
Challenges Ahead
- Risk that BARDA may not exercise all contract options.
- Risk of not completing contracts on schedule or according to terms.
- Risk of contracts being modified or canceled by the U.S. government.
- Uncertainty in the development of the international biodefense market.
- Potential impact of the COVID-19 pandemic on operations and supply chain.
Revenue & Expenses
Visualization of income flow from segment revenue to net income